Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
Opus Genetics (Nasdaq: IRD) management will participate in a fireside chat at the Guggenheim Annual Healthcare Innovation Conference on November 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Opus Genetics (Nasdaq: IRD) management will participate in a fireside chat at the Guggenheim Annual Healthcare Innovation Conference on November 10, 2026. The session is scheduled for 11:00 a.m. ET. A live and archived webcast will be available through the Events page in the Investors section of the company’s website.
Details
News Market Reaction – IRD
On Nov 3, the day this news came out, IRD closed 6.22% above the previous close. Argus tracked a peak move of +3.6% during that session. Our momentum scanner recorded 19 alerts for this stock that day.
Data tracked by StockTitan Argus for the Nov 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will participate in a Fireside Chat at the Guggenheim Annual Healthcare Innovation Conference on Tuesday, November 10, 2026 at 11:00 a.m. ET.
A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with OPGx-RDH12 cleared to enter the clinic, and additional candidates targeting, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, N.C. For more information, visit www.opusgtx.com.
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.
